Jing Wang

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Prognostic Factors

Chemotherapy Induced

Systemic Lupus Erythematosus

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer. Cancer research communications 3 (6) (2023)
Jing Wang, Renfang Zhang, Xiangqing Ding, Yanling Jin, Ran Qin, Bili Xia, Qibin Liao, Huiliang Hu, Wei Song, Zhenyan Wang, Xiaoyan Zhang, Jianqing Xu
Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient. Immunotherapy 14 (8) (2022)